More Posts

Regeneron’s $256M 23andMe Buy: 15M Genomes & R&D Benefits
Regeneron’s $256M 23andMe Buy: 15M Genomes & R&D Benefits

Regeneron Pharmaceuticals has agreed to acquire almost all of 23andMe’s business lines, whic...

Barrington James

By Barrington James